Possible involvement of the locus coeruleus in inhibition by prostanoid EP3 receptor-selective agonists of morphine withdrawal syndrome in rats

European Journal of Pharmacology

Volumn 390, Issue 3, 2000, Pages 257-266

  Nakagawa, Takayuki ^a   Masuda, Takahiro ^a   Watanabe, Takeshi ^a   Minami, Masabumi ^a   Satoh, Masamichi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Opioid receptor; c fos; Locus coeruleus; Morphine withdrawal; Prostaglandin; Prostanoid EP3 receptor

Indexed keywords

11 DEOXY 16 PHENOXY 17,18,19,20 TETRANORPROSTAGLANDIN E1; MESSENGER RNA; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; PROSTANOID RECEPTOR; PROTEIN C FOS; RECEPTOR SUBTYPE; SULPROSTONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; DRUG DEPENDENCE; HYPOTHALAMUS; IN SITU HYBRIDIZATION; LOCUS CERULEUS; MALE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RAT; THALAMUS; WITHDRAWAL SYNDROME;

ALPROSTADIL; ANIMALS; BRAIN; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; IN SITU HYBRIDIZATION; INJECTIONS, INTRAVENTRICULAR; LOCUS COERULEUS; MALE; MORPHINE; MORPHINE DEPENDENCE; NALOXONE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU; RECEPTORS, PROSTAGLANDIN E; RNA, MESSENGER; SUBSTANCE WITHDRAWAL SYNDROME; TYROSINE 3-MONOOXYGENASE;

EID: 0034598992     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00901-2     Document Type: Article

References (52)

1. Aghajanian G.K. Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine. Nature. 276:1978;186-188.
2. Ammer H., Schulz R. Alterations in the expression of G-proteins and regulation of adenylate cyclase in human neuroblastoma SH-SY5Y cells chronically exposed to low efficacy μ-opioids. Biochem. J. 295:1993;263-271.
3. Beckmann A.M., Matsumoto I., Wilce P.A. Immediate early gene expression during morphine withdrawal. Neuropharmacology. 34:1995;1183-1189.
4. Bhargava H.N. Diversity of agents that modify opioid tolerance, physical dependence, abstinence syndrome, and self-administrative behavior. Pharmacol. Rev. 46:1994;293-324.
5. Calvino B., Lagowska J., Ben-Ari Y. Morphine withdrawal syndrome: differential participation of structures located within the amygdaloid complex and striatum of the rats. Brain Res. 177:1979;19-34.
6. Chahl L.A., Johnston P.A. Effect of the nonpeptide NK-1 receptor antagonist CP-96,345 on the morphine withdrawal response of guinea pigs. Regul. Pept. 46:1993;373-375.
7. Coleman R.A., Smith W.L., Narumiya S. International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46:1994;205-229.
8. Collier H.O.J. Cellular site of opiate dependence. Nature. 283:1980;625-629.
9. Dafny N. Interferon modifies morphine withdrawal phenomena in rodents. Neuropharmacology. 22:1983;647-651.
10. DiStefano P.S., Brown O.M. Biochemical correlates of morphine withdrawal: 2. Effects of clonidine. J. Pharmacol. Exp. Ther. 233:1985;339-344.
11. 2 on noradrenaline release in the mouse brain cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 351:1995;46-52.
12. Fundytus M.E., Coderre T.J. Morphine dependence is affected by activity at metabotropic, as well as ionotropic (NMDA), glutamate receptors. Br. J. Pharmacol. 113:1994;1215-1220.
13. Fundytus M.E., Ritchie J., Coderre T.J. Attenuation of morphine withdrawal symptoms by subtype-selective metabotropic glutamate receptor antagonists. Br. J. Pharmacol. 120:1997;1015-1020.
14. Gibson R.D., Tingstad J.E. Formulation of a morphine implantation pellet suitable for tolerance - physical dependence studies in mice. J. Pharm. Sci. 59:1970;426-427.
15. Hayward M.D., Duman R.S., Nestler E.J. Induction of the c-fos proto-oncogene during opiate withdrawal in the locus coeruleus and other regions of rat brain. Brain Res. 525:1990;256-266.
16. Ichikawa A., Sugimoto Y., Negishi M. Molecular aspects of the structures and functions of the prostaglandin E receptors. J. Lipid Mediators Cell Signalling. 14:1996;83-87.
17. Katsumata S., Minami M., Nakagawa T., Satoh M. Intracisternal administration of interleukin-1β attenuates naloxone-precipitated withdrawal in morphine-dependent mice. Eur. J. Pharmacol. 278:1995;143-150.
18. Koob G.F., Maldonado R., Stinus L. Neural substrates of opiate withdrawal. Trends Neurosci. 15:1992;186-191.
19. Kreeger J.S., Larson A.A. Substance P-(1-7), a substance P metabolite, inhibits withdrawal jumping in morphine-dependent mice. Eur. J. Pharmacol. 238:1993;111-115.
20. Maekawa K., Minami M., Masuda T., Satoh M. Expression of μ- and κ-, but not δ-, opioid receptor mRNAs is enhanced in the spinal dorsal horn of the arthritic rats. Pain. 64:1995;365-371.
21. Maldonado R. Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci. Biobehav. Rev. 21:1997;91-104.
22. Maldonado R., Girdlestone D., Roques B.P. RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats. Neurosci. Lett. 156:1993;135-140.
23. Maldonado R., Stinus L., Gold L.H., Koob G.F. Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J. Pharmacol. Exp. Ther. 261:1992;669-677.
24. 2-like mammalian octapeptide: possible role in opiate dependence and abstinence. Peptides. 11:1990;969-972.
25. Malin D.H., Lake J.R., Leyva J.E., Hammond M.V., Rogillio R.B., Arcangeli K.R., Ludgate K., Moore G.M., Payza K. Analog of neuropeptide FF attenuates morphine abstinence syndrome. Peptides. 12:1991;1011-1014.
26. Marek P., Ben-Eliyahu S., Gold M., Liebeskind J.C. Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in rats. Brain Res. 547:1991;77-81.
27. Marek P., Ben-Eliyahu S., Vaccarino A.L., Liebeskind J.C. Delayed application of MK-801 attenuates development of morphine tolerance in rats. Brain Res. 558:1991;163-165.
28. Minami M., Maekawa K., Yabuuchi K., Satoh M. Double in situ hybridization study on coexistence of μ-, δ- and κ-opioid receptor mRNAs with preprotachykinin A mRNA in the rat dorsal root ganglia. Mol. Brain Res. 30:1995;203-210.
29. Minami M., Onogi T., Toya T., Katao Y., Hosoi Y., Maekawa K., Katsumata S., Yabuuchi K., Satoh M. Molecular cloning and in situ hybridization histochemistry for rat μ-opioid receptor. Neurosci. Res. 18:1994;315-322.
30. Minami M., Satoh M. Molecular biology of the opioid receptors: structures, functions and distributions. Neurosci. Res. 23:1995;121-145.
31. Morgan J.I., Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu. Rev. Neurosci. 14:1991;421-451.
32. 3 receptor. Br. J. Pharmacol. 116:1995;2661-2666.
33. Nestler E.J. Molecular mechanisms of drug addiction. J. Neurosci. 12:1992;2439-2450.
34. Nestler E.J., Aghajanian G.K. Molecular and cellular basis of addiction. Science. 278:1997;58-63.
35. Nestler E.J., Hope B.T., Widnell K.L. Drug addiction: a model for the molecular basis of neural plasticity. Neuron. 11:1993;995-1006.
36. 3 receptors. Brain Res. 663:1994;287-292.
37. Okutomi T., Nishizawa T., Inagawa H., Soma G., Minami M., Satoh M., Mizuno D. Inhibition of morphine dependence by a lipopolysaccharide from Pantoea agglomerans. Eur. Cytokine Network. 3:1992;417-420.
38. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, Australia.
39. Rasmussen K., Beitner-Johnson D.B., Krystal J.H., Aghajanian G.K., Nestler E.J. Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical correlates. J. Neurosci. 10:1990;2308-2317.
40. Rasmussen K., Brodsky M., Inturrisi C.E. NMDA antagonists and clonidine block c-fos expression during morphine withdrawal. Synapse. 20:1995;68-74.
41. Sharma S.K., Klee W.A., Nirenberg M. Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc. Natl. Acad. Sci. U. S. A. 72:1975;3092-3096.
42. Sheng M., Greenberg M.E. The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron. 4:1990;477-485.
43. Silverstone P.H., Done C., Sharp T. Clonidine but not nifedipine prevents the release of noradrenaline during naloxone-precipitated opiate withdrawal: an in vivo microdialysis study in the rat. Psychopharmacology. 109:1992;235-238.
44. Stornetta R.L., Norton F.E., Guyenet P.G. Autonomic areas of rat brain exhibit increased Fos-like immunoreactivity during opiate withdrawal in rats. Brain Res. 624:1993;19-28.
45. 3 subtype. J. Biol. Chem. 267:1992;6463-6466.
46. 3 in the mouse nervous system. Neuroscience. 62:1994;919-928.
47. Taylor J.R., Elsworth J.D., Garcia E.J., Grant S.J., Roth R.H., Redmond D.E. Jr. Clonidine infusions into the locus coeruleus attenuate behavioral and neurochemical changes associated with naloxone-precipitated withdrawal. Psychopharmacology. 96:1988;121-134.
48. 2+ entry. Brain Res. 425:1987;101-105.
49. Vargas M.L., Martínez-Piñero M.G., Milanés M. Neurochemical activity of noradrenergic neurons and pituitary-adrenal response after naloxone-induced withdrawal: the role of calcium channels. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:1997;501-506.
50. Vela G., Ruiz-Gayo M., Fuentes J.A. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology. 34:1995;665-668.
51. Yabuuchi K., Minami M., Katsumata S., Satoh M. In situ hybridization study of interleukin-1β mRNA induced by kainic acid in the rat brain. Mol. Brain Res. 20:1993;153-161.
52. Zhu Y.S., Inturrisi C.E. Metrazole induction of c-fos and proenkephalin gene expression in the rat adrenal and hippocampus: pharmacological characterization. Mol. Brain Res. 20:1993;118-124.